CJC-1295
These sentences are taken from FDA’s compounding-risk page and, where noted, the July 2026 advisory-committee agenda. They are not a finding that a substance works.
What the opened sources say
Section titled “What the opened sources say”- CJC-1295 is on the withdrawn-nomination list. FDA says compounded drugs containing it may pose an immunogenicity risk for certain routes and may be difficult to characterize.
- FDA says it has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and that available clinical data are limited.
Not stated here
Section titled “Not stated here”Legal effect beyond the words on those pages is not interpreted. No animal or human study is summarized, because none was opened.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (primary, accessed 2026-11-20)
- July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (primary, accessed 2026-11-20)
Referenced by
- BPC-157
- FDA Category 2 and withdrawn nominations
- GHK-Cu
- Ipamorelin
- Melanotan II
- MOTS-c
- PCAC meeting, 23–24 July 2026
- Peptides
- TB-500
A link from another wiki page is not evidence. Facts should point at the sources above.